Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil infusion alone during closure in supratentorial craniotomy
NCT02593942Phase 4Completed
- Sponsor
- Yeditepe University Hospital
- Start
- Jan 2015
- Primary completion
- Sep 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of remifentanil in supratentorial neoplasm (2 arms), sponsored by Yeditepe University Hospital. Primary endpoint: Time of extubation at 3 hours. Started Jan 2015; status: completed.
02
Drugs
remifentanil
03
Conditions
supratentorial neoplasm
Beyond the preview
Go deeper on NCT02593942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593942.